Dr. Miao is responsible for antibody discovery and critical reagent development. He earned his Ph.D. from China Pharmaceutical University and participated in a joint training program at the University of California, Los Angeles. Previously, he served as Senior Manager of Antibody Development and Engineering at Innovent Biologics (Suzhou) Co., Ltd., where he led numerous national class I new drug projects, including monoclonal and bispecific antibody initiatives, successfully advancing these projects into CMC development and clinical trials. Currently, Dr. Miao is focused on establishing the antibody screening platform at Biotheus. His work emphasizes antibody discovery and engineering for new drug projects, the preparation of critical reagents, and the oversight of advancements in bispecific antibody projects.